Patel VA, Ratner D
There have been notable advances in the management of advanced cutaneous malignancies over the last 18 months. With the advent of targeted molecular therapies, clinicians are able to target inoperable tumors by manipulating specific biomolecular machinery, rendering the current treatment options for metastatic as well as advanced melanomas and nonmelanoma skin cancers (NMSCs) obsolete. As the incidence and prevalence of melanoma and NMSCs continue to rise, the number of advanced or unresectable cases has also increased. Furthermore, as solid organ transplantation and long-term immunosuppressive medications become more common, increasing numbers of aggressive cutaneous malignancies have been reported.